# A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

> **NCT04165031** · PHASE1,PHASE2 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 5 (actual)

## Conditions studied

- Advanced Solid Tumor
- Non-Small Cell Lung Cancer
- Colorectal Cancer

## Interventions

- **DRUG:** LY3499446
- **DRUG:** Abemaciclib
- **DRUG:** Cetuximab
- **DRUG:** Erlotinib
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT04165031
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-11-28
- **Primary completion:** 2020-10-30
- **Final completion:** 2020-10-30
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** The study was terminated due to an unexpected toxicity finding.
- **Last updated:** 2021-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04165031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04165031, "A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04165031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*